This Phase I study enrolled R/R AML fit pts, with CD33 expression on >25% of leukemic blasts….The trial enrolled 4 cohorts with Lintuzumab-Ac225 at doses ranging from 0.25 uCi/kg to 1.0 uCi/kg.For high-risk patients, 42% (n=8) of patients achieved CRc (CR+CRi), and 16% (n=3) achieved MLFS, for an overall response rate (ORR) of 58%. Among patients achieving CRc, 71% achieved MRD negativity by flow cytometry. In all high-risk patients, the median OS was 7.3 months…CLAG-M followed by Lintuzumab-Ac225 yielded significantly better clinical outcomes in high-risk populations, particularly in patients previously treated with venetoclax combinations.